Macrogenics (MGNX) Income from Continuing Operations (2012 - 2026)
Macrogenics (MGNX) posted quarterly Income from Continuing Operations of 38908000.0 for Q1 2026, up 8.91% year-over-year from 35724070.76 in Q1 2025, and down 175.42% quarter-over-quarter from 14127000.0 in Q4 2025.
Powered by 
Analysis
Macrogenics (MGNX) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Income from Continuing Operations for 15 consecutive years, with 38908000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 8.91% year-over-year to 38908000.0; the TTM figure through Mar 2026 stood at 72464000.0 (down 26.04% YoY), while the FY2025 annual figure was 74592000.0, down 11.39% from the prior year.
- Income from Continuing Operations declined to 38908000.0 in Q1 2026 per MGNX's latest filing, from 14127000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 56309000.0 in Q3 2024 and bottomed at 100195000.0 in Q1 2024.
- Historically, Income from Continuing Operations has averaged 31213882.35 across 5 years, with a median of 38908000.0 in 2026.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations plunged 511.87% — and 2024, when it surged 258.61%.
- Macrogenics' Income from Continuing Operations stood at 11983000.0 in 2022, then slumped by 511.87% to 49354000.0 in 2023, then soared by 68.75% to 15421000.0 in 2024, then advanced by 8.39% to 14127000.0 in 2025, then tumbled by 175.42% to 38908000.0 in 2026.
- Business Quant data shows MGNX's Income from Continuing Operations at 38908000.0 in Q1 2026, 14127000.0 in Q4 2025, and 16822000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Macrogenics | 277.59 Mn | 163.68 Mn | - | -69.64 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -69.64 Mn |
| Mar 31, 2026 | -38.33 Mn |
| Dec 31, 2025 | -14.13 Mn |
| Sep 30, 2025 | 16.82 Mn |
| Jun 30, 2025 | -42.72 Mn |
| Mar 31, 2025 | -42.72 Mn |
| Dec 31, 2024 | -15.42 Mn |
| Sep 30, 2024 | 56.31 Mn |
| Jun 30, 2024 | -55.66 Mn |
| Mar 31, 2024 | -54.88 Mn |
| Dec 31, 2023 | -49.35 Mn |
| Sep 30, 2023 | -35.50 Mn |
| Jun 30, 2023 | -45.74 Mn |
| Mar 31, 2023 | -39.08 Mn |
| Dec 31, 2022 | 11.98 Mn |
| Sep 30, 2022 | -24.96 Mn |
| Jun 30, 2022 | -41.81 Mn |
| Mar 31, 2022 | -66.64 Mn |
| Dec 31, 2021 | -58.24 Mn |
| Sep 30, 2021 | -52.99 Mn |